Q-omics provides the consensus-scored MIR3130-2 profile across patient tissues and cancer cell-line models. MIR3130-2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR3130-2 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR3130-2 RNA expression shows 6,653 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, BRCA, and LIHC as cancer lineages where MIR3130-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3130-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3130-2 survival associations across molecular data types. MIR3130-2 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3130-2 RNA expression–survival associations across cancer types. High MIR3130-2 expression shows unfavorable associations in KIRC, ESCA, COAD, LIHC and UCEC, but favorable associations in GBM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR3130-2 RNA expression.
This table summarizes MIR3130-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3130-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3130-2 shows lower tumor expression in BRCA, COAD and THCA and higher tumor expression in LUAD. The BRCA box plot shows higher MIR3130-2 RNA expression in normal versus tumor tissue (log2 FC = −0.249, t-test p = .002).
This table shows molecular features associated with MIR3130-2 in patient tissues and cancer cell lines. In patient samples, MIR3130-2 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
